President & CEO
Sarah Boyce is president, CEO and a board member at Avidity, where she has served since 2019. With more than 25 years of global leadership experience in the pharmaceutical and biopharmaceutical industries, she has played a key role in advancing RNA-based therapeutics.
Under Sarah’s leadership, Avidity has transitioned from an R&D-focused organization to a clinical-stage biopharmaceutical company, with three RNA therapies in clinical development and continued expansion of its proprietary RNA technology platform.
Before joining Avidity, Sarah was president and board member at Akcea Therapeutics and held executive roles at Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche.
She has been recognized as a Top 25 Biotech CEO by the Healthcare Technology Report and named one of the Fiercest Women in Life Sciences. Sarah currently serves on the boards of Contineum Therapeutics and Abcuro and holds a B.Sc. (Hons) in microbiology from the University of Manchester, England.